anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to the delivery of beta-blockers through an inhalation route. Specifically, it relates to aerosols containing atenolol, pindolol, esmolol, propranolol, or metoprolol that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of atenolol, pindolol, esmolol, propranolol, or metoprolol. In a method aspect of the present invention, one of atenolol, pindolol, esmolol, propranolol, or metoprolol is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of atenolol, pindolol, esmolol, propranolol, or metoprolol, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering atenolol, pindolol, esmolol, propranolol, or metoprolol through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of atenolol, pindolol, esmolol, propranolol, or metoprolol; and, b) a device that forms a atenolol, pindolol, esmolol, propranolol, or metoprolol containing aerosol from the composition, for inhalation by the mammal.
The present invention is a grain product. The grain product includes a first fraction including bran. The first fraction is milled to a first particle size of less than 500 micrometers. The grain product also includes a second fraction including germ. The second fraction is milled to a second particle size of less than 500 micrometers. The grain product is at least one of: a food product, a nutritional supplement, a dietary supplement, a fiber supplement, a digestive supplement, a functional food, and a medical food.
Cardiovascular diseases are the foremost contributor to global mortality, presenting a complex etiology and an expanding array of risk factors. Coronary artery disease characterized by atherosclerotic plaque build-up in the coronary arteries, imposes significant mortality and financial burdens, especially in low- and middle-income nations. The pathogenesis of coronary artery disease involves a multifaceted interplay of genetic, environmental, and epigenetic factors. Epigenetic regulation contributes to the dynamic control of gene expression without altering the underlying DNA sequence. The mounting evidence that highlights the pivotal role of epigenetic regulation in coronary artery disease development and progression, offering potential avenues for the development of novel diagnostic biomarkers and therapeutic targets. Abnormal DNA methylation patterns are linked to the modulation of gene expression involved in crucial processes like lipid metabolism, inflammation, and vascular function in the context of coronary artery disease. Cell-free DNA has become invaluable in tumor biology as a liquid biopsy, while its applications in coronary artery disease are limited, but intriguing. Atherosclerotic plaque rupture causes myocardial infarction, by depriving heart muscles of oxygen, releasing cell-free DNA from dead cardiac cells, and providing a minimally invasive source to explore tissue-specific epigenetic alterations. We discussed the methodologies for studying the global methylome and hydroxy-methylome landscape, their advantages, and limitations. It explores methylome alterations in coronary artery disease, considering risk factors and their relevance in coronary artery disease genesis. The review also details the implications of MI-derived cell-free DNA for developing minimally invasive biomarkers and associated challenges.
A technique for promoting the assimilation of an oligosaccharide such as an HMO by an intestinal bacterium, especially a bifidobacterial strain, is provided. As a first aspect, a composition for promoting the assimilation of an oligosaccharide containing a tocopherol is provided. As a second aspect, a nutritional composition (excluding breast milk) containing an oligosaccharide and a tocopherol is provided. The tocopherol in the aspects contains one, two or more kinds selected from the group consisting of β-tocopherol, γ-tocopherol and δ-tocopherol. The oligosaccharide in the aspects is preferably a human milk oligosaccharides. The mass ratio of the δ-tocopherol content to the β-tocopherol content (δ/β) in the aspects is preferably 5 or more, and the mass ratio of the γ-tocopherol content to the δ-tocopherol content (γ/δ) is preferably 8.8 or less.
The patient, an 83-year-old woman, was diagnosed with ER- and PgR-positive left breast cancer(T2N0M0, Stage ⅡA) at the age of 68. At the time, she underwent preoperative chemotherapy followed by Bp+Ax and postoperative radiotherapy to the conserved breast. She also received endocrine therapy as adjuvant therapy. At the age of 73, she underwent radiotherapy for multiple bone metastases and left axillary lymphadenectomy due to left axillary lymph node recurrence. After surgery, she received 4 regimens of endocrine therapy over a period of 5 years and 1 month for bone metastases. At the age of 79, S-1 was administered for pulmonary metastasis which continued for the next 2 years and 8 months. At the age of 81, palbociclib+letrozole were administered for 1 year and 8 months owing to the progression of bone metastases. At the age of 83, she developed liver metastases and was administered ethinyl estradiol, starting at 1.5 mg/day and continued at a reduced dose of 0.5 mg/day for 9 months. The reduction in tumor markers after treatment initiation was rapid, and there were no serious adverse events. Ethinyl estradiol was useful for maintaining QOL in this elderly patient with recurrent breast cancer.
The invention discloses a chemically modified osteoclast, a preparation method and application. The chemically modified osteoclast is obtained by modifying osteoclast with tetracycline or tetracycline salt. The preparation method comprises the following steps: (1) obtaining osteoclasts; (2) mixing tetracycline or tetracycline salt with osteoclast, and amidating to obtain tetracycline modified osteoclast. The invention enhances the adhesion and targeting of the tetracycline or tetracycline salt to ectopic calcified tissues through surface modification of the tetracycline or tetracycline salt, and leads osteoclast to deacidify and phagocytize pathological calcification. The present invention follows the concept of HO to validate cell therapy by chemically modifying HO to control OC function at the single cell level. This chemical incorporation of functional materials on cells has shown promise in drug testing for a variety of diseases.
The present invention pertains to a method for identifying and/or characterizing a compound suitable for the prevention and/or treatment of a disease. The invention is based on the finding that the glycolytic enzyme Enolase 1 (ENO1) binds RNA, and its enzymatic activity is thereby regulated. The invention is further based on the finding that riboregulation of ENO1 affects cell differentiation, which plays a pivotal role in cancer. Accordingly, the invention provides a screening method for novel therapeutic compounds based on the binding of RNA to ENO1. Compounds screened according to the present invention can affect the binding of RNA to ENO1, which harbors the therapeutic potential for the treatment of diseases, in particular proliferative diseases, such as cancer. Methods of treatment using these compounds, as well as pharmaceutical compositions thereof, are also provided.
PROBLEM TO BE SOLVED: To obtain a peritoneum dialyzing fluid which is rapidly metabolized, not accumulated in the body, is inexpensive, excellent in dehydrating performances and dehydrating time and low in glucose absorption and is useful in renal insufficiency, etc., by including glucose and maltose as osmotic pressure adjusting substances in a specific ratio. SOLUTION: This dialyzing fluid comprises (A) glucose and (B) maltose as osmotic pressure adjusting solutions in the molar ratio of 1:0.05 to 5. The dialyzing fluid is adjusted to 280-600 mOSM/kg osmotic pressure and to pH 6.0-7.5. Preferably the total of the components A and B is about 0. 5-5 g/dl. The dialyzing fluid can miniaturize a bag containing a peritoneum dialyzing fluid, reduce a storage place for the bag containing a peritoneum dialyzing fluid and lessen a waste and greatly contributes to rehabilitation, etc., of patients.
This invention, which focuses on personality and aptitude matching by psychophysiologic response to stimuli, is referred to as Brain Matching. In general terms, this invention starts by selecting highly specialized skill sets and top performer group for each skill set. The various groups are analyzed though psychophysiologic stimuli testing by using basically the same testing consisting of large numbers stimuli tests in a consistent testing environment. Stimuli tests can range from hundreds to thousands of images each producing a brainwave response. Neural Networks, Artificial Intelligence, Deep Learning computers look at the test results, highly specialized group by other highly specialized group to reduce the groups signature/response commonality into a template. Test subjects are then tested using the same stimuli. The subject's test results are analyzed for correlation with the various specialized expert groups.
BACKGROUND: Stellate ganglion block (SGB) may have protective effects in patients at risk of vasospasm following subarachnoid hemorrhage (SAH) due to reduced sympathetic activity. However, the safety and clinical outcomes of SGB in this scenario are not definitively known. The objective was to evaluate the safety, clinical outcomes, and cerebral blood flow velocity in patients submitted to SGB or cervical sympathectomy with SAH.
METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, a systematic review and meta-analysis of studies investigating SGB or cervical sympathectomy use in SAH were conducted. PubMed, Cochrane Library, and Embase were evaluated. Patients with mRS from 0 to 2, GOS from 4 to 5, or symptom resolution were considered favorable clinical outcomes. Related mortality was defined as death by vasospasm or delayed cerebral ischemia.
RESULTS: The analysis included 8 studies comprising 182 patients. Only 2 studies employed SGB prophylactically. The results revealed favorable outcomes in 52% of patients (95% CI: 37%-65%). The overall incidence of complications was 2% (95% CI: 0% -26%). The mortality rate was 13% (95% CI: 7%-21%), with a vasospasm-related mortality rate of 11% (95% CI: 2%-20%). A decrease of cerebral blood flow velocity was reported in 4 studies.
CONCLUSIONS: The notable reduction in cerebral blood flow velocity following SGB, alongside positive outcomes and a low occurrence of mortality and complications, highlights its significance as a therapeutic intervention for vasospasm following SAH. While the number of studies evaluating SGB as a preventive measure is limited, the promising results emphasize the importance of future research.
Patients will receive toripalimab and induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent toripalimab of 240mg will be administered every 3 weeks for 3 cycles during IMRT. Toripalimab 240mg will be given every 3 weeks for 13 cycles, started on day 1 of induction chemotherapy.
According to the present invention, by a functional cosmetic composition utilizing natural plant extracts, an effect of maximizing skin protection is ensured. In addition, due to a cosmetic composition for cool cream using a chrysanthemum extract, which is a natural plant extract, anti-inflammatory and cooling effects are ensured. Thus, convenient usage is possible irrespective of places. The present invention relates to a sunblock or cool cream cosmetic composition containing a natural plant extract. The present invention relates to a cosmetic composition for producing sunblock or cool cream by using a natural plant extract. To this end, a method for producing a skin moisturizing nutrient cream composition comprises the steps of: producing a pine needle liquid extract, an onion liquid extract, a green tea liquid extract, and a grape liquid extract; producing a mixture by mixing alkaline ionized water, a pine needle liquid extract, an onion liquid extract, a green tea liquid extract, a grape liquid extract, and an additive; fermenting the mixture to perform solid/liquid separation into a precipitate and a supernatant; filtering the solid/liquid separated mixture to collect the supernatant; producing gel by gelling the supernatant; and quenching the gel to the room temperature. A nutrient cream composition produced according to the present invention is made of a natural material, and thus does not cause a side effect to a human body. Penetrating power to the skin and moisture fixing functions in the stratum corneum are excellent, and a moisturizing effect is excellent.
THALOMID is known to cause nerve damage that may be permanent. Peripheral neuropathy is a common (≥10%) and potentially severe adverse reaction of treatment with THALOMID that may be irreversible. Peripheral neuropathy generally occurs following chronic use over a period of months; however, peripheral neuropathy following relatively short-term use has been reported. The correlation with cumulative dose is unclear. Symptoms may occur some time after THALOMID treatment has been stopped and may resolve slowly or not at all.

Few reports of neuropathy have arisen in the treatment of ENL despite long-term THALOMID treatment. However, the inability clinically to differentiate THALOMID neuropathy from the neuropathy often seen in ENL makes it difficult to determine accurately the incidence of THALOMID-related neuropathy in patients with ENL treated with THALOMID.

Patients should be examined at monthly intervals for the first 3 months of THALOMID therapy to enable the clinician to detect early signs of neuropathy, which include numbness, tingling or pain in the hands and feet. Patients should be evaluated periodically thereafter during treatment. Patients should be regularly counseled, questioned, and evaluated for signs or symptoms of peripheral neuropathy. Consideration should be given to electrophysiological testing, consisting of measurement of sensory nerve action potential (SNAP) amplitudes at baseline and thereafter every 6 months in an effort to detect asymptomatic neuropathy. If symptoms of drug-induced neuropathy develop, THALOMID should be discontinued immediately to limit further damage, if clinically appropriate. Usually, treatment with THALOMID should only be reinitiated if the neuropathy returns to baseline status.

Medications known to be associated with neuropathy should be used with caution in patients receiving THALOMID [see Drug Interactions (7.3)].
This invention provides neuromedin U 2 receptor (NMU-2R) agonists. This invention further provides a method for screening and identification of said agonist. This invention also provides the core structure for NMU-2R agonists. This invention provides that the agonist can effectively reduced body weight of high fat diet induced obese rats and normal C57BL/6 mice. In addition, the compound increased the insulin sensitivity and decreased blood glucose level of obese rats. Specifically, this invention provides that Rutin and the related compounds could be developed into effective therapeutic drugs for obesity and non-insulin dependent diabetes mellitus (NIDDM).
Neuroinflammation contributes to impaired cognitive function in brain aging and neurodegenerative disorders like Alzheimer's disease, which is characterized by the aggregation of pathological tau. One major driver of both age- and tau-associated neuroinflammation is the NF-κB and NLRP3 signaling axis. However, current treatments targeting NF-κB or NLRP3 may have adverse/systemic effects, and most have not been clinically translatable. In this study, we tested the efficacy of a novel, nucleic acid therapeutic (Nanoligomer) cocktail specifically targeting both NF-κB and NLRP3 in the brain for reducing neuroinflammation and improving cognitive function in old (aged 19 months) wildtype mice, and in rTg4510 tau pathology mice (aged 2 months). We found that 4 weeks of NF-κB/NLRP3-targeting Nanoligomer treatment strongly reduced neuro-inflammatory cytokine profiles in the brain and improved cognitive-behavioral function in both old and rTg4510 mice. These effects of NF-κB/NLRP3-targeting Nanoligomers were also associated with reduced glial cell activation and pathology, favorable changes in transcriptome signatures of glia-associated inflammation (reduced) and neuronal health (increased), and positive systemic effects. Collectively, our results provide a basis for future translational studies targeting both NF-κB and NLRP3 in the brain, perhaps using Nanoligomers, to inhibit neuroinflammation and improve cognitive function with aging and neurodegeneration.
Human pluripotent stem (hPS) cells can, in theory, be differentiated into any cell type, making them a powerful in vitro model for human biology. Recent technological advances have facilitated large-scale hPS cell studies that allow investigation of the genetic regulation of molecular phenotypes and their contribution to high-order phenotypes such as human disease. Integrating hPS cells with single-cell sequencing makes identifying context-dependent genetic effects during cell development or upon experimental manipulation possible. Here we discuss how the intersection of stem cell biology, population genetics and cellular genomics can help resolve the functional consequences of human genetic variation. We examine the critical challenges of integrating these fields and approaches to scaling them cost-effectively and practically. We highlight two areas of human biology that can particularly benefit from population-scale hPS cell studies, elucidating mechanisms underlying complex disease risk loci and evaluating relationships between common genetic variation and pharmacotherapeutic phenotypes.
PROBLEM TO BE SOLVED: To improve the particle characteristic and tablet property by setting the content of hydroxypropoxyl group and apparent average degree of polymerization within specific ranges. SOLUTION: This cellulose contains 5.0-16.0 wt.% of hydroxypropoxyl group, and has an apparent average degree of polymerization of 350-700, pref. 400-600. This degree of polymerization is attained by controlling degree of polymerization of raw material, reaction temp., reaction time, etc., in its production process. If degree of polymerization is lower than 350, the strength of granulation becomes high and disintegration times of the compressed product becomes long, and if degree of polymerization is higher than 700 granulate strength is lowered, and hardness of the compressed product becomes insufficient. Further, it is pref. that the cellulose has a volume average particle size by dry laser diffraction method of 10-100 μm, and a bulk density a (little hard) of 0.4-0.8 g/ml. It is preferable that the content of the cellulose in a tablet is 5-50 wt.%.
Participants will complete a screening visit to determine study eligibility. Eligible subjects will be scheduled to begin 22 days of study participation. During the first week, participants will be randomly assigned to take either progesterone or placebo (inactive medication) twice a day, and to abstain from marijuana use. During this week, participants will upload videos of themselves taking their medication and performing saliva drug tests. They will collect and store additional saliva samples each morning for hormone testing. They will also participate in "CREMA" sessions (Cue Reactivity Ecologic Momentary Assessment) three times a day. These sessions include looking at stressful and neutral pictures and rating stress and craving. At the end of this week, participants will return to the clinic and participate in a stress task. For the next two weeks, participants will continue to collect saliva samples and participate in CREMA sessions. They will return at the end of the two weeks to return study supplies. Urine samples will be collected at each study visit.
PURPOSE: To obtain a solid form preparation product comprising a lubricating polymer and a sialogogue and useful for relieving xerostomia syndrome and reducing symptoms thereof. CONSTITUTION: This solid form preparation product comprises 0.001-50 wt.% lubricating polymer comprising polyethylene oxide and 0.1-2 wt.% sialogogue (e.g. citric acid) as an active ingredient in a non-cariogenic carrier. Further, the preparation contains a mineral ion source and a fluorine source. The carrier contains sorbitol or a combination of the sorbitol with xylitol, and the polyethylene oxide is used alone or in a mixture with a mucin, a cellulose gum, a polycarbophil, etc. The preparation can be formed into a pharmaceutical form of a troche, a tablet, a chewing gum, a pill, etc.
Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, intravenous infusion of propofol, lidocaine, ketamine or narcotic as deemed appropriate by anesthesiologist. There will be no inhalation anesthetic used. Ventilation with oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During surgery, mechanical ventilation using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.